C12N 2830/008
Cell type or tissue specific enhancer/promoter combination
Official title: cell type or tissue specific enhancer/promoter combination
C12N2830/008 (Cell type or tissue specific enhancer/promoter combination) appears on 1,375 US grants and 2,447 published applications in this corpus.
Search patents in C12N- Granted patents
- 1,375
- Published applications
- 2,447
- Assignees
- 972
- Inventors
- 4,165
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 2 | 0 |
| 1993 | 3 | 0 |
| 1994 | 7 | 0 |
| 1995 | 7 | 0 |
| 1996 | 15 | 0 |
| 1997 | 33 | 0 |
| 1998 | 46 | 0 |
| 1999 | 46 | 0 |
| 2000 | 43 | 0 |
| 2001 | 56 | 18 |
| 2002 | 38 | 83 |
| 2003 | 48 | 128 |
| 2004 | 30 | 122 |
| 2005 | 33 | 115 |
| 2006 | 43 | 109 |
| 2007 | 50 | 96 |
| 2008 | 46 | 85 |
| 2009 | 43 | 77 |
| 2010 | 52 | 88 |
| 2011 | 44 | 62 |
| 2012 | 38 | 57 |
| 2013 | 41 | 43 |
| 2014 | 30 | 45 |
| 2015 | 34 | 56 |
| 2016 | 31 | 65 |
| 2017 | 48 | 73 |
| 2018 | 37 | 83 |
| 2019 | 45 | 75 |
| 2020 | 57 | 86 |
| 2021 | 45 | 118 |
| 2022 | 60 | 158 |
| 2023 | 52 | 154 |
| 2024 | 50 | 153 |
| 2025 | 61 | 176 |
| 2026 | 59 | 122 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Interneuron-specific therapeutics for normalizing neuronal cell excitability and treating Dravet syndrome29 Sep 2026US 12,747,452 B2New York University
- Gene-therapy vectors for treating cardiomyopathy29 Sep 2026US 12,747,453 B2
- Gene-therapy vectors for treating cardiomyopathy22 Sep 2026US 12,742,181 B2
- Gene therapy for treatment of CRX-autosomal dominant retinopathies1 Sep 2026US 12,721,908 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Lentiviral vectors in hematopoietic stem cells to treat Wiskott-Aldrich syndrome (WAS)25 Aug 2026US 12,714,732 B2The Regents of the University of California
- Epigenetic repression protein therapy for rasopathies8 Oct 2026US 2026/0306675 A1Battelle Memorial Institute
- Adeno-associated virus vector delivery of b-sarcoglycan and microrna-29 and the treatment of muscular dystrophy8 Oct 2026US 2026/0308212 A1Research Institute At Nationwide Children's Hospital
- Gene therapy for lysosomal acid lipase deficiency (lal-d)8 Oct 2026US 2026/0308547 A1Research Institute At Nation Wide Children's Hospital
- Compositions and methods for the treatment of neuromuscular disorders8 Oct 2026US 2026/0308613 A1Astellas Gene Therapies, Inc.
- Compositions comprising smyd1 and methods of use thereof8 Oct 2026US 2026/0308621 A1
Most cited
By later US patents
- Transgenic non-human animals capable of producing heterologous antibodies of various isotypes1,748US 5,569,825 AGenPharm International, Inc. · 1996
- Regulation of endogenous gene expression in cells using zinc finger proteins648US 6,534,261 B1Sangamo BioSciences, Inc. · 2003
- Isolation of exogenous recombinant proteins from the milk of transgenic mammals500US 4,873,316 ABiogen, Inc. · 1989
- Transgenic mice depleted in a mature lymphocytic cell-type491US 5,591,669 AGenPharm International, Inc. · 1997
- Regulation of endogenous gene expression in cells using zinc finger proteins395US 6,824,978 B1Sangamo BioSciences, Inc. · 2004